Non-absorbable implants better in the long-term

Article

The use of implants in deep sclerectomy enhances success rates and lowers the need for postoperative medications, according to Petr Strnad, MD and colleagues from the Masaryk University, Czech Republic.

The use of implants in deep sclerectomy enhances success rates and lowers the need for postoperative medications, according to Petr Strnad, MD and colleagues from the Masaryk University, Czech Republic.

They conducted a retrospective review of 86 eyes of 56 patients who had undergone deep sclerectomy, with at least five-years follow-up. The patients were divided into three groups according to the type of surgery. The first group underwent deep sclerectomy without implant (40 eyes, 26 patients); the second underwent deep sclerectomy with an absorbable collagen implant (24 eyes, 16 patients) and the third group underwent deep sclerectomy with a non-absorbable implant (22 eyes, 14 patients).

The average preoperative intraocular pressure (IOP) of the three groups was recorded at 25.3, 25.9 and 23.7 mmHg, respectively and the number of anti-glaucoma medications was 3.1, 3.2 and 3.4. Mean follow-up time was 81.6, 78 and 69.8 months, respectively.

Average IOP, at the end of the follow-up period, was 17.25 mmHg for the group with no implant, 16.7 mmHg for those with the absorbable implant and 16.5 mmHg for those with the non-absorbable implant. The number of anti-glaucoma medications was 2.1, 1.6 and 0.8, respectively.

The researchers discovered that patients who received an implant during surgery achieved better outcomes than those who did not and that non-absorbable implants, in particular, offered better long-term IOP compensation than absorbable implants.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
Related Content
© 2025 MJH Life Sciences

All rights reserved.